ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

XLO vs HRTX // 10Y YIELD & FRED MACRO BETA

Xilio Therapeutics Inc. (NASDAQ) VS. Heron Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: XLO 3 — HRTX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XLO VS. HRTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC XLO HRTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 73.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -10.78% — — TIE /fcf-yield <GO>
Operating Margin -60.00% -1.60% -58.40 HRTX /operating-margins <GO>
Net Profit Margin -60.00% -12.90% -47.10 HRTX /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 XLO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.1 37.6 +4.50 XLO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $52.8M $52.7M $116.6K XLO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR XLO REV HRTX REV XLO GROSS % HRTX GROSS % XLO FCF HRTX FCF
FY 2025 $43.8M $154.9M — 73.3% -$5.5M -$27.9M
FY 2024 $6.3M $144.3M — 73.2% -$18.4M -$24.2M
FY 2023 $221.6M $309.7M — — -$68.6M -$58.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XLO // BETA —
HRTX // BETA —